Gleicher Norbert, Barad David H, Patrizio Pasquale, Gayete-Lafuente Sonia, Weghofer Andrea, Rafael Zion Ben, Takahashi Shizuko, Glujovsky Demián, Mol Ben W, Orvieto Raoul
Center for Human Reproduction (CHR), New York, NY, USA.
Foundation for Reproductive Medicine, New York, NY, USA.
J Assist Reprod Genet. 2025 Jan;42(1):71-80. doi: 10.1007/s10815-024-03318-z. Epub 2024 Dec 18.
After over 20 years of progressively increasing clinical utilization of PGT-A (and its precursors), the American Society for Reproductive Medicine (ASRM) and its daughter society, the Society for Assisted Reproduction (SART), for the first time published a committee opinion clearly acknowledging that "the value of PGT-A as a routine screening test for patients undergoing in vitro fertilization (IVF) has not been demonstrated." This statement is timely and welcome but requires some additions and raises some new questions, among those why, if PGT-A in a general population does not improve IVF cycle outcomes, the routine clinical utilization of PGT-A should continue.
在对胚胎植入前遗传学检测（PGT-A）（及其前身）进行了20多年的临床应用逐步增加之后，美国生殖医学学会（ASRM）及其附属学会辅助生殖学会（SART）首次发表了一份委员会意见，明确承认“PGT-A作为体外受精（IVF）患者常规筛查检测的价值尚未得到证实”。这一表述适时且值得欢迎，但需要补充一些内容并引发了一些新问题，其中包括，如果在普通人群中PGT-A并不能改善IVF周期结局，那么为何PGT-A的常规临床应用仍应继续。
